CEO of MariMed Buys 75,000 Shares After RSU Conversion, Signaling Confidence
CEO’s May 7 buy of 75k MariMed shares at $0.09 suggests hidden value and a bullish outlook amid regulatory shifts and planned Massachusetts expansion.
4 minutes to read
MariMed Inc
Insider RSU Sales at MariMed: COO Shaw Timothy’s Big Move Raises Investor Concerns
Insider selling signals: COO Shaw Timothy’s 170k‑RSU sale amid MariMed’s sharp decline and social‑media spike—why it matters for investors and future earnings.
4 minutes to read
Shaw Timothy’s April 2 MariMed Trades Show Steady Executive Confidence – What Investors Should Watch
Shaw Timothy’s April 2 insider trades show measured equity management, not speculation—steady COO activity may boost investor confidence amid MariMed’s biotech journey.
4 minutes to read
Shaw Timothy’s RSU Conversion Boosts MariMed Shares—What It Means for Investors
Shaw Timothy’s recent RSU conversion at MariMed shows routine equity activity, not a major shift—focus on upcoming production approvals and sector trends.
3 minutes to read